#RNL2021 coverage by @uptoTate for #RheumNow https://t.co/x1GjGGNPii

• https://twitter.com/uptotate/status/1373355123620077576

Great #RNL2021 coverage by @KDAO2011 for #RheumNow https://t.co/GBnlyvPaz1

• https://twitter.com/kdao2011/status/1373279374225588231

Liver Management in RA - #RNL2021 Highlight by @DrPetryna While RA is not known to affect the liver directly, underlying liver disease and treatment-related effects on the liver can often become an obstacle in the mgmt of many RA patients. https://t.co/OeuloDIXMF

• https://buff.ly/3cbpHtG

New RheumNow Podcast Now Available! Infection in ANCA-Associated Vasculitis https://t.co/Twy04G9RU1 Download wherever podcasts are available!

• https://buff.ly/3fjQBlo

RheumNow Podcast – Infection in ANCA-Associated Vasculitis Dr. Jack Cush reviews the news, FDA Denials and journal articles from the past week on https://t.co/4GKxMY5Lll https://t.co/joi1puBSuX

• https://buff.ly/2cpUCWC
• https://buff.ly/3fhzK2i

#RNL2021 coverage from @KDAO2011 #RheumNow https://t.co/GBnlyvPaz1

• https://twitter.com/kdao2011/status/1373279374225588231

Are You a Super Rheum? https://t.co/omvQXwhcoV https://t.co/8iQaRAi5di

• https://buff.ly/3cp3B7j

Analysis of CPRD registry and 15670 MTX treated pts (46,571 PYs) showed discontinuation for abnormal or severely abnormal labs was 42/1000PY and 6/1,000PY; half that after Yr 1 (22 & 2.84). D/C for severe labs was 1 in 169 Yr1 & 1 in 352 per year after https://t.co/Dx91YqjplT

• https://buff.ly/39hCyJ7

#RNL2021 Highlights: Future Therapeutics for Rheumatoid Arthritis and Lessons Learned https://t.co/NxLyHeI2f4 https://t.co/df7lPEia0D

• https://buff.ly/3rmIQxk

News Feature: FDA Panel Rejects Tanezumab for Osteoarthritis A 2 day FDA review by the Drug Safety and Risk Management and Arthritis Advisory Committees has yielded a 19-1 vote against the approval of tanezumab for use in OA. https://t.co/ltKmm9Nl1y https://t.co/qTWhSX9LBd

• https://buff.ly/3tOxJii

The Reflecting Rheum: Top Publications from 2020 Covering SpA and Still’s Disease Sponsored by Novartis Medical Affairs Listen to a panel of experts share their views on top spondyloarthritis and Still’s disease publications from 2020. View Now: https://t.co/Kp2drDAqFv https://t.co/tjkUpxcMdT

• https://buff.ly/3tHTsbA

#RNL2021 coverage from @uptoTate #RheumNow https://t.co/u11ltNc2vA

• https://twitter.com/uptotate/status/1373280485456146434

The RheumNow podcast is up--Great Associations Dr. Jack Cush rants on the journal reports, news and FDA actions featured last week on RheumNow. https://t.co/gzWVbL8xMJ

• https://buff.ly/3fc6B8T